John Murphy

Thanks again to our attendees, sponors, speakers and panelists! Here’s your Day 2 Recap, from #access2026! accessiblemeds.org/resources/blog…

And that's a wrap! 🎉 Thank you to our AAM event planning team, all attendees, every dedicated sponsor and the speakers, panelists and moderators who truly are the future of generic and biosimilar medicines. YOU are driving what's next for the generic and biosimilar medicines industry—and we are thrilled to see the positive impact we can bring to America's patients when we all work together toward better access to lower-cost prescription medicines. Thanks again for joining us in sunny South Florida! ☀️ Get home safely, everyone!

More exciting news today, for our member company Lupin Pharmaceuticals, with CEO Vinita Gupta being named to the CNBC's Changemakers list of Women Transforming Business. Congrats, Vinita! cnbc.com/vinita-gupta-2…

Huge thank you to Joseph M. Shields, Esq, Chief Executive Officer, @transparency_rx and Matt Wetzel, JD, Partner, Goodwin Procter LLP for another invigorating panel discussion. Keeping in-line with the "future" theme for #Access2026, and moderated by AAM's @JAMurphy_III, the discussion offered an overview and implications of the Consolidated Appropriations Act of 2026.

And the #Access2026 Lifetime Achievement Award goes to… Scott Cornwell, CEO, @DispensaryHope. Congratulations Scott. SO WELL DESERVED! 👏

We’d also like to extend gratitude for Punit Patel of Zydus Pharmaceuticals, who has stepped into the role of Vice Chair for our association’s board!

With thanks to Keren Haruvi for her dedication and success as former AAM Board Chair, we are now thrilled to welcome Bob Hoffman of @LupinGlobal – as our new Chairman of the AAM Board of Directors! Bob most recently served as Vice-Chair with our AAM board, and we are greatly looking forward to all the future holds under his leadership. Congrats to you, Bob!

If you are attending our annual meeting, #access2026, please post your favorite moments and tag us, here on X! #access2026 READ our #access day 1 recap: accessiblemeds.org/resources/blog…

👏 What an incredible close to our day one main-stage activity, here at #Access2026! Attendees were on the edge of their seats as top analysts weighed in on the economic and investment climate impacting medicines. A giant thank you to Andy Bressler, MBA of @BankofAmerica, Michael DiFiore, PharmD, MBA of Evercore, Ipsita Smolinski, MBA of Capitol Street and moderator Jayson Slotnik, JD, MPH of Health Policy Strategies. Make sure to join us back on all AAM social channels tomorrow – as Access! 2026 continues from bright and beautiful Aventura, Florida!

With more than 180 million Americans receiving health benefits through their job, employers are uniquely impacted by the market for pharmacy benefit (PBM) services; and employers are also among those most strongly advocating for reform. Our #Access2026 Fireside Chat with @JamesGelfand just wrapped, and explored employers’ efforts to address PBM business practices and what comes next in the debate over PBMs and their role in our healthcare system. Big thanks to James Gelfand, JD, President and CEO, The ERISA Industry Committee (ERIC) and Executive Director, @BiosimsCouncil and Senior Vice President, Policy, AAM, Alex Keeton, for this essential discussion.

And that's a wrap for our first panel discussion of the day: “Navigating the Current Political Landscape: Implications for Generic and Biosimilar Policy.” A big thank you to @MsCEAntelo, Esq, Founding Principal and Chief Executive Officer, @FeroxStrategies, Kate Hull, Senior Vice President, Fierce Government Relations and our own Senior Vice President, Government Affairs, AAM, Mark Ratner – who moderated this morning's discussion.

There is (a warm South Florida) buzz in the air! 🌴 With our #Access2026 Business Expo Meet & Greet complete and the official Access! Welcome Reception well underway, attendees are getting ready for tomorrow's line-up - with discussions on the Current Political Landscape and Implications for Generic and Biosimilar Policy, Wall Street Perspectives, with Market Trends and Expectations, and More! We'd like to take this time to extend a warm thank you to our Access! 2026 event sponsors, speakers and attendees. We can't wait to see all that's in-store at the generic and biosimilar medicines INDUSTRY EVENT OF THE YEAR! access.accessiblemeds.org

#Access2026 member meetings have begun here in beautiful Aventura, Florida! Stay tuned to our #AAM channels this week as Access attendees dive into what the future of generic and biosimilar medicines holds for America's patients and the U.S. healthcare ecosystem. access.accessiblemeds.org

Robert Foster, Chief Counsel for Food, Research, and Drugs at HHS, joins AAM President & CEO @JAMurphy_III and AAM Board Chair Bob Hoffman to discuss key policy and advocacy issues. Don’t miss this high‑impact fireside chat at #Access2026. access.accessiblemeds.org

Join us at #Access2026 for a timely conversation on the evolving political landscape shaping generic & biosimilar policy. Hear the latest from Washington and how advocacy is driving access to affordable medicines. Register now: access.accessiblemeds.org

Yesterday, AAM president & CEO John Murphy III joined key healthcare experts before @HouseCommerce , where he outlined four key policy areas Congress can act on RIGHT NOW to protect generic and biosimilar medicines and provide more sustainable access and lower costs for patients, and enormous savings for the healthcare ecosystem. READ MORE in Chain Drug Review: chaindrugreview.com/aams-john-murp… @JAMurphy_III @BiosimsCouncil @Chaindrugreview

Join us for #Access2026, Feb 23–25 in South Florida! AAM’s annual meeting brings together policymakers, industry leaders & global experts to shape the future of #generics & #biosimilars. Register today: access.accessiblemeds.org

HAPPENING NOW @HouseCommerce: "Congress has a real opportunity to unlock even greater savings simply by allowing these [generic and biosimilar medicines] markets to function as intended. Generics are the only sector of the prescription drug market where total spending has declined over time, even as volume has increased." -AAM president and CEO @JAMurphy_III WATCH: youtu.be/_vpu-DZRrE8

Today our AAM team applauded passage of Q1/Q2 legislation as a part of the FY2026 funding bill and called on Congress to take additional steps to reform PBMs. Q1/Q2 will cut red tape, save the U.S. healthcare system over one billion dollars, and bring lower-cost medicines to patients sooner. AAM also commended Congress for enacting initial PBM reforms, but calls for stronger, more robust measures to reign in PBM practices. Read our full press release: accessiblemeds.org/resources/pres…

The #Access2026 speaker lineup is here! Leaders in #generics, #biosimilars are shaping the future of #healthcare. Join us at Access! 2026 to help move the conversation forward. Register: access.accessiblemeds.org